27.74
+0.34(+1.24%)
Currency In USD
Address
171 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America
Phone
650 489 9000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
40
First IPO Date
January 11, 2021
| Name | Title | Pay | Year Born |
| Craig C. Parker | Chief Executive Officer, President & Director | 892,375 | 1962 |
| Li Yang | Executive Vice President of Research | 579,850 | 1969 |
| Charles Williams | Chief Operating Officer & Corporate Secretary | 647,639 | 1980 |
| Calvin Kuo | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Roeland Nusse | Co-Founder & Member of Scientific Advisory Board | 0 | 1950 |
| Esther Jhun | Controller | 0 | N/A |
| Andrew Maleki | CFO & Principal Financial & Accounting Officer | 0 | 1989 |
| Daniel L. Chao | Vice President and Head of Clinical Development | 0 | N/A |
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.